Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Pujade-Lauraine, E., Selle, F., Scambia, G., Asselain, B., Marmé, F., Lindemann, K., Colombo, N., Mądry, R., Glasspool, R., Vergote, I., Korach, J., Lheureux, S., Dubot, C., Oaknin, A., Zamagni, C., Heitz, F., Gladieff, L., Rubio-Pérez, M.J., Scollo, P., Blakeley, C., Shaw, B., Ray-Coquard, I., Redondo, A.
Published in Annals of oncology (01.12.2023)
Published in Annals of oncology (01.12.2023)
Get full text
Journal Article
1687P Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Rubio Pérez, M.J., Sanchez, A.B., Maximiano Alonso, C., Garcia Garcia, Y., Alfaro, N., Rubio Renau, R., Solà, C., Bolea, S., Quindós, M.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
718MO Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial
Secord, A.A., Corr, B.R., Lewin, S., Diver, E., Ayuk, S-M., Wang, Y., Murphy, C., Salutari, V., Garcia, A. Barquin, Montosa, F. Galvez, Ray-Coquard, I.L., Mathews, C., Konecny, G.E., Oaknin, A., Pérez, M.J. Rubio, Bonaventura, A., Pignata, S.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
722P Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
Gladieff, L., Martinez-Garcia, J., Takekuma, M., Villacampa, G., De Giorgi, U., Harter, P., Hellman, K., Duska, L., Ortiz, A. Godoy, Bellier, C., Nishio, H., Pérez, M.J. Rubio, Delanoy, N., Madrid, L. Fariñas, Berton, D., Alarcon, J.D., Kurtz, J.E., Nishino, K., Randall, L.M., Oaknin, A.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Poveda, A., Lheureux, S., Colombo, N., Cibula, D., Lindemann, K., Weberpals, J., Bjurberg, M., Oaknin, A., Sikorska, M., González-Martín, A., Madry, R., Pérez, M.J. Rubio, Ledermann, J., Davidson, R., Blakeley, C., Bennett, J., Barnicle, A., Škof, E.
Published in Gynecologic oncology (01.03.2022)
Published in Gynecologic oncology (01.03.2022)
Get full text
Journal Article
LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
Pujade-Lauraine, E., Selle, F., Scambia, G., Asselain, B., Marmé, F., Lindemann, K., Colombo, N., Madry, R., Glasspool, R.M., Dubot, C., Oaknin, A., Zamagni, C., Heitz, F., Gladieff, L., Rubio-Pérez, M.J., Scollo, P., Blakeley, C., Shaw, B., Ray-Coquard, I.L., Redondo, A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer
Pignata, S., Marth, C., Moore, R.G., Bidzinski, M., Ayhan, A., Pérez, M.J. Rubio, Beiner, M., Hall, M., Vulsteke, C., Braicu, I., Sonoda, K., Wu, X., Frentzas, S., Mattar, A., McKenzie, J., Yao, L., Khemka, V., Gilbert, L., Makker, V.
Published in ESMO open (01.06.2024)
Published in ESMO open (01.06.2024)
Get full text
Journal Article
51P Efficacy and safety by time to maintenance therapy treatment initiation in PRIMA/ENGOT-OV26/GOG-3012
Haslund, C.A., Willmott, L.J., Pérez, M.J. Rubio, Cloven, N., Van den Bulck, H.F.M., Moore, R.G., Pisano, C., O'Cearbhaill, R.E., Selle, F., Pothuri, B., Harter, P., Ghamande, S., Bruchim, I., Disilvestro, P., Ginesta, M.P. Barretina, Koliadi, A., Malinowska, I., York, W., González-Martín, A., Monk, B.J.
Published in ESMO open (01.06.2024)
Published in ESMO open (01.06.2024)
Get full text
Journal Article
43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O
Trillsch, F., Okamoto, A., Kim, J-W., Reuss, A., Pérez, M.J. Rubio, Vardar, M.A., Salutari, V., Frenel, J-S., Kärkkäinen, H., Colombo, N., Chudecka-Glaz, A.M., Oppelt, P., Lheureux, S., Lamot, C., Engler, T., Wenham, R.M., Nishio, S., Correa, A., Harter, P., Aghajanian, C.
Published in ESMO open (01.06.2024)
Published in ESMO open (01.06.2024)
Get full text
Journal Article
531P Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
Poveda Velasco, A.M., Lheureux, S., Colombo, N., Cibula, D., Elstrand, M., Weberpals, J., Bjurberg, M., Oaknin, A., Sikorska, M., Gonzalez Martin, A.J., Madry, R., Rubio Perez, M.J., Ledermann, J.A., Ozgoren, O., Barnicle, A., Marshall, H., Bashir, Z., Skof, E.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
Oaknin, A., Gladieff, L., Martinez-Garcia, J., Villacampa, G., Takekuma, M., De Giorgi, U.F.F., Lindemann, K., Woelber, L., Colombo, N., Duska, L.R., Leary, A., Godoy Ortiz, A., Nishio, S., Angelergues, A., Rubio Perez, M.J., Fariñas Madrid, L., Yamaguchi, S., Lorusso, D., D'Hondt, V., Randall, L.
Published in Annals of oncology (01.12.2023)
Published in Annals of oncology (01.12.2023)
Get full text
Journal Article
LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Gonzalez Martin, A., Rubio Perez, M.J., Heitz, F., Christensen, R.D., Colombo, N., Van Gorp, T., Oaknin, A., Leary, A., Gaba Garcia, L., Lebreton, C., De Sande González, L.M., Romeo Marin, M., Redondo, A., Barretina Ginesta, M.P., Perez Fidalgo, J.A., Santaballa Bertran, A., Bermejo-Pérez, M.J., Bruchim, I., Ray-Coquard, I.L., Selle, F.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
770P Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Rubio Perez, M.J., Manzano Fernández, A., De Sande González, L.M., Estevez Garcia, P., Gordon Santiago, M.D.M., Soto de Prado, D., Hernando Fernandez, B.A., Guerra Alia, E.M., Carbo Bague, A., Romero, I., Corbellas Aparicio, M., Gonzalez-Haba Martinez, A., Robles Barraza, C.E., Martinez-Garcia, J., Gonzalez Martin, A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
795P Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Cueva Banuelos, J.F., Salvador Coloma, C., Galvez Montosa, F., Ferreiro Quintana, J., Cros Costa, S., González-Santiago, S., Cassinello, J.G., Romeo Marin, M., Reche, P., Soriano Tabares, M.L., Valero Arbizu, M., Rubio Perez, M.J., Oré Arce, H.M., Gaba Garcia, L., Gordon Santiago, M.D.M., Gomez Raposo, C., Hernando Polo, S., Marquez Vazquez, R., Fuentes Pradera, J., Gonzalez Martin, A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
38MO Validation study of the ShallowHRDv2 assay for homologous recombination deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial
Callens, C., Rodrigues, M.J., Briaux, A., Browaeys, E., Eeckhoutte, A., Pujade-Lauraine, E., Renault, V., Stoppa-Lyonnet, D., Bieche, I., Bataillon, G., Heitz, F., Chiara-Cecere, S., Rubio Perez, M.J., Berger, R., Jakobi Nøttrup, T., Colombo, N., Vergote, I.B., Ray-Coquard, I.L., Stern, M-H., Popova, T.
Published in ESMO open (01.02.2023)
Published in ESMO open (01.02.2023)
Get full text
Journal Article
Toxicidad cutánea asociada a la administración de paclitaxel
Pérez Rodrigo, I., Rubio Pérez, M.J., Albornoz López, R., Abellón Ruiz, J.
Published in Farmacia hospitalaria (01.08.2008)
Published in Farmacia hospitalaria (01.08.2008)
Get full text
Journal Article
Recurrencia de un carcinoma gástrico de células en anillo de sello demostrada por PET-FDG
Ruiz-Hernández, G., Delgado-Bolton, R.C., Rubio-Pérez, M.J., Jiménez-Vicioso, A., Pérez-Castejón, M.J., Carreras-Delgado, J.L.
Published in Revista española de medicina nuclear (2005)
Published in Revista española de medicina nuclear (2005)
Get full text
Journal Article